Van Hulzen Asset Management LLC Makes New Investment in LeMaitre Vascular, Inc. $LMAT

Van Hulzen Asset Management LLC acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 9,991 shares of the medical instruments supplier’s stock, valued at approximately $959,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Sound Income Strategies LLC increased its stake in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC purchased a new stake in shares of LeMaitre Vascular during the 1st quarter worth approximately $32,000. Geneos Wealth Management Inc. boosted its holdings in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular in the 2nd quarter valued at $47,000. Finally, Quarry LP raised its stake in LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 529 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Get LeMaitre Vascular alerts:

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $79.96 on Tuesday. The firm’s fifty day moving average price is $94.14 and its 200 day moving average price is $99.62. LeMaitre Vascular, Inc. has a 1-year low of $78.65 and a 1-year high of $118.01. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 28.06, a price-to-earnings-growth ratio of 2.36 and a beta of 0.53.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.07). The firm had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 earnings per share. On average, sell-side analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular’s payout ratio is 35.09%.

Wall Street Analyst Weigh In

Several research firms have issued reports on LMAT. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Wells Fargo & Company decreased their target price on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 5th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, August 14th. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $110.60.

Check Out Our Latest Research Report on LeMaitre Vascular

About LeMaitre Vascular

(Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

Featured Stories

• Five stocks we like better than LeMaitre Vascular
• Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
• Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
• Snowflake Could Be Headed for New Highs Despite Insider Selling
• MongoDB Is Surging—And the Next Catalyst Is Almost Here

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report).

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.